SavedAdd your journal

Journals / Marmara Pharmaceutical Journal / 2018 / Cilt: 22 - Sayı: 2

Development and in vitro evaluation of positive-charged solid lipid nanoparticles as nucleic acid delivery system in glioblastoma treatment

GÜLŞAH EREL AKBABA
HASAN AKBABA
A. Gülten KANTARCI
Pages
299–306
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Based on these findings, we propose that the developed cSLN system may has a potential as a siRNA delivery system for glioblastoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we aimed to develop a novel positive charged nucleic acid delivery system for the treatment of glioblastoma.
📊
Key Findings & Data:Cationic solid lipid nanoparticles (cSLN) were developed by microemulsion dilution method using cetyl palmitate as matrix lipid, Cremephor RH40 and Peceol as surfactants, and ethanol as cosurfactant.
💡
Conclusion & Impact:Based on these findings, we propose that the developed cSLN system may has a potential as a siRNA delivery system for glioblastoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

In this study, we aimed to develop a novel positive charged nucleic acid delivery system for the treatment of glioblastoma. For this purpose, Epidermal Growth Factor Receptor (EGFR) which plays a prominent role in glioblastoma was selected as a target. Cationic solid lipid nanoparticles (cSLN) were developed by microemulsion dilution method using cetyl palmitate as matrix lipid, Cremephor RH40 and Peceol as surfactants, and ethanol as cosurfactant. Characterization studies showed that obtained nanoparticles are positively charged and has an appropriate particle size for nucleic acid delivery (<20 nm). Gel retardation assay revealed that cSLNs have complexation ability with siRNA EGFR (cSLN:siRNAEGFR) and this complex is able to protect siRNA from serum‐ mediated degradation up to 6 h. The cytotoxicity evaluation of nanoparticles performed on U87 Human Glioblastoma Cell Line. Furthermore, in vitro delivery of siRNA-EGFR via cSLN inhibited EGFR expression significantly at 50nM siRNA dose compared to free siRNA-EGFR at the same dose on U87 cell line (p<0.05). Based on these findings, we propose that the developed cSLN system may has a potential as a siRNA delivery system for glioblastoma.

🔖

Cite This Article

AKBABA, G. E., AKBABA, H., KANTARCI, A. G. (2018). Development and in vitro evaluation of positive-charged solid lipid nanoparticles as nucleic acid delivery system in glioblastoma treatment. Marmara Pharmaceutical Journal, Cilt: 22 - Sayı: 2, 299–306. https://ajindex.com/articles/283600

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Alifieris C, Trafalis DT. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol Ther. 2015; 152: 63-82
  2. Danhier F, Messaoudi K, Lemaire L, Benoit J-P, Lagarce F. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation. Int J Pharm. 2015; 481(1–2): 154–161
  3. Brower JV, Clark PA, Lyon W, Kuo JS. MicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem cells. Neurochem Int. 2014; 77: 68–77
  4. Wang G, Wang JJ, Tang HM, To SST. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Arch Biochem Biophys. 2015; 580: 64–74
  5. Kuşçu L, Sezer AD. Gen Tedavisi İçin Tasarlanan ve Patent Başvurusu Yapılan Farmasötiklerin İncelenmesi ve Değerlendirilmesi. Marmara Pharm J. 2016; 20(2): 52-63
  6. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56(9): 1257–1272
  7. Yang S, Zheng Y, Chen J, Zhang Q, Zhao D, Han D, Chen X. Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. Coll Surf B. 2013; 101: 6–13
  8. Uprit S, Kumar Sahu R, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 2013; 21(4): 379–385
  9. Büyükköroğlu G, Şenel B, Başaran E, Yenilmez E, Yazan Y. Preparation and in vitro evaluation of vaginal formulations including siRNA and paclitaxel-loaded SLNs for cervical cancer. Eur J Pharm Biopharm. 2016; 109: 174–183
  10. Jin SE, Kim CK. Charge-mediated topical delivery of plasmid DNA with cationic lipid nanoparticles to the skin. Coll Surf B. 2014; 116: 582–590
  11. Kotmakçı M, Akbaba H, Erel G, Ertan G, Kantarcı G. Improved Method for Solid Lipid Nanoparticle Preparation Based on Hot Microemulsions: Preparation, Characterization, Cytotoxicity, and Hemocompatibility Evaluation. AAPS PharmSciTech. 2017; 18(4): 1355-1365
  12. Resnier P, David S, Lautram N, Delcroix GJR, Clavreul A, Benoit JP. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. Int J Pharm. 2013; 454(2): 748–755
  13. Van Woensel M, Wauthoz N, Rosière R, Mathieu V, Kiss R, Lefranc F. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. J Control Release. 2016; 227: 71–81
  14. Kotmakçı M, Çetintaş VB, Kantarcı AG.